In this study, we explored a novel combination of antibodies targeting CD3, BAFF-R, and PD-L1, and investigated the therapeutic potential of combining them with an HDAC inhibitor to enhance anti-tumor effects by modulating antigenic strength and the immunosuppressive environment. Here, CD274 is linked to neoplasm.